Could Australia be your fast track to global oncology development?
Discover how to maximize Australia’s early-phase advantages while preparing for FDA expectations and global development.
For biotech sponsors in China and across APAC, Australia has become a compelling location for Phase 1 oncology studies, combining regulatory efficiency with a mature clinical research ecosystem. When designed with global objectives in mind, these studies don’t just move faster – they can generate globally relevant data to advance broader regulatory and development goals.
In this webinar, you’ll hear from a former FDA oncology regulator, an experienced Phase 1 investigator and global development specialists as they explore how to make the most of Australia’s early-phase opportunities while laying the groundwork for future international trials.
Register to Watch Webinar
The right decisions now can amplify what’s next.
Hear what our panel has to say about the advantages of getting started in Australia. Discover how early development decisions and evolving regulatory expectations can shape your international ambitions.
- Your Australian head start
Explore how Australia's efficient regulatory pathways can help sponsors accelerate study startup and gain momentum in early clinical development. - Building globally relevant evidence from Day 1
Learn what makes Australian Phase 1 data particularly valuable in a broader development context and the considerations that can maximize its impact. - Anticipating the FDA
Understand how early regulatory engagement and evolving FDA expectations, including Project Optimus, can influence your approach to dose optimization and evidence generation. - Sharpening your Phase 1 strategy
Gain practical perspectives on study design and site selection, including why early investigator engagement can make a difference to patient recruitment. - Your launchpad for global development
Discover how Australian trial data can contribute to a broader international strategy, and what sponsors should consider when planning for future regulatory submissions.
Hear from those who know what it takes.
What does the FDA look for in early oncology development? And what can sponsors learn from those already navigating the challenges of taking a program onto the global stage? Our panel brings together first-hand regulatory insight and practical experience of running early-phase oncology trials in Australia and beyond.
-
-
-
Charlotte Lemech, MBBS, BSc(med), FRACP, MD(res)
Medical Director, Medical Oncologist
-